Meeting Report
2022–2023 Drug Updates in Solid Tumors
Presented by Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
From UConn School of Pharmacy and UConn Health Carole & Ray Neag Comprehensive Cancer Center and Department of Pharmacy, Mansfield, Connecticut
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2024;15(3):170–176 |
https://doi.org/10.6004/jadpro.2024.15.3.3 |
© 2024 BroadcastMed LLC
ABSTRACT
At JADPRO Live 2023 in Orlando, Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, briefed advanced practitioners on key US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Holle described indications, mechanisms of action, and monitoring and management of side effects of new therapies in solid malignancies.
For access to the full length article, please
sign in.
